XML 28 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1

Accounts payable and accrued expenses

12 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

Accounts payable and accrued expenses

6. Accounts payable and accrued expenses

Accounts payable and accrued expenses at December 31, 2023 and 2022 consist of the following:

​

​	​	​	​	​	​	​
​	​	December 31,
​	​	2023			2022
Employee compensation, benefits, and related accruals	​	$	62,643	​	$	62,669
Income tax payable	​	​	—	​	​	4,712
Consulting and contracted research	​		27,500	​		38,882
Professional fees	​		2,246	​		3,093
Sales allowance	​		77,176	​		63,787
Sales rebates	​		131,334	​		67,355
Royalties	​	​	74,111	​	​	40,546
Accounts payable	​		6,045	​		27,268
Other	​		10,928	​		12,054
Total	​	$	391,983	​	$	320,366

​

During the year ended December 31, 2023, the Company incurred $32.8 million of restructuring costs from a reduction in workforce in connection with the Company’s strategic pipeline prioritization and discontinuation of its preclinical and early research programs in its gene therapy platform. The costs are included in research and development and selling, general and administrative expenses on the Company’s consolidated statement of operations. As of December 31, 2023, the remaining $9.0 million of accrued restructuring costs are included above within employee compensation, benefits, and related accruals.

X

- Definition

The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.

+ References

No definition available.

+ Details

Name:	us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration